Search results for "MICROENVIRONMENT"

showing 10 items of 369 documents

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

2021

High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) &gt

Oncologymedicine.medical_specialtyMyeloidmyeloid markersT cellCD3gastroenteropancreatic neuroendocrine neoplasms; myeloid markers; tumor microenvironmentCD33PopulationHuman leukocyte antigenSettore MED/08 - Anatomia PatologicaArticleSurgical pathology03 medical and health sciences0302 clinical medicineInternal medicinemedicinetumor microenvironmenteducation030304 developmental biologymyeloid marker0303 health sciencesTumor microenvironmenteducation.field_of_studybiologybusiness.industryRGeneral Medicinegastroenteropancreatic neuroendocrine neoplasms myeloid markers tumor microenvironmentgastroenteropancreatic neuroendocrine neoplasmsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisgastroenteropancreatic neuroendocrine neoplasmbiology.proteinMedicinebusiness
researchProduct

Prognostic Impact of Immune Microenvironment Markers in Tumor and Stroma in Resectable Nsclc

2014

ABSTRACT Aim: Tumor-infiltrating immune cells have been proved to play an important role in tumor progression. In this study we have analyzed the expression of 11 immune related genes in both tumor and stroma samples of resectable NSCLC patients. Methods: In this retrospective study FFPE samples from 117 early-stage NSCLC patients of primary tumor tissue were used. The most representative areas of tumor and tumor stroma of each sample were carefully micro-dissected. RT-PCR using hydrolysis probes (TaqMan, Applied Biosystems) was performed to assess the expression of Treg markers such as: CD127, CD25, FOXP3, CTLA-4, IL-10, TGFB-1, LAG-3, GITR and TNFA as well as CD4 and CD8. Relative gene ex…

Oncologymedicine.medical_specialtyTumor microenvironmentbusiness.industryFOXP3Hematologymedicine.diseasePrimary tumorOncologyStromaTumor progressionInternal medicinemedicineCancer researchIL-2 receptorProgression-free survivalbusinessCD8Annals of Oncology
researchProduct

Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study

2021

Background The search for treatments to improve cancer survival has led to the emergence of immunotherapy and the study of the tumour microenvironment existing in neoplasms. This preliminary study aims to understand the clinical and pathological relationship of clec9a expression in oral cancer and to explore survival models for future studies. Material and methods: Immunohistochemical study that included 26 patients with a diagnosis of oral squamous cell carcinoma (OSCC) in mobile tongue and floor of the mouth. Clinical and histopathological variables were recorded, and the biomarkers clec9a for dendritic cells and CD8 and CD4 for lymphocytes were used. Results Clec9a was expressed in 58% o…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPilot ProjectsInternal medicineOral Cancer and Potentially malignant disordersmedicineCarcinomaTumor MicroenvironmentHumansLectins C-TypepainGeneral DentistryPathologicalSurvival analysisUNESCO:CIENCIAS MÉDICASMouth neoplasmTumor microenvironmentbusiness.industryResearchquestionnaireCancerpsychometric validationImmunotherapymedicine.diseasePrognosisstomatognathic diseasesOtorhinolaryngologydisabilityHead and Neck NeoplasmsReceptors MitogenCarcinoma Squamous CellImmunohistochemistrySurgeryMouth Neoplasmshead and neck cancerbusiness
researchProduct

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

2019

International audience; In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leu…

PD-L10301 basic medicinePrognosiSettore MED/06 - Oncologia Medica[SDV]Life Sciences [q-bio]medicine.medical_treatmentImmunologyPredictive significance[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemNeoplasmsImmune suppressionPD-1Biomarkers TumormedicineAnimalsHumansTumor microenvironmentTumor-infiltrating lymphocytesMelanomaImmunotherapyPrognosismedicine.diseaseImmune checkpoint3. Good healthImmunosurveillance030104 developmental biologyTumor microenvironment030220 oncology & carcinogenesisCancer cellTumor immunologyCancer researchImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTumor-infiltrating lymphocytes (TILs)Cellular Immunology
researchProduct

Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation

2015

Bone disease is the most frequent complication in multiple myeloma (MM) resulting in osteolytic lesions, bone pain, hypercalcemia and renal failure. In MM bone disease the perfect balance between bone-resorbing osteoclasts (OCs) and bone-forming osteoblasts (OBs) activity is lost in favour of OCs, thus resulting in skeletal disorders. Since exosomes have been described for their functional role in cancer progression, we here investigate whether MM cell-derived exosomes may be involved in OCs differentiation. We show that MM cells produce exosomes which are actively internalized by Raw264.7 cell line, a cellular model of osteoclast formation. MM cell-derived exosomes positively modulate pre-…

Pathologymedicine.medical_specialtyCellular differentiationCellOsteoclastsMMP9BiologyExosomesMiceOsteoclastMultiple myelomaSettore BIO/13 - Biologia ApplicatamedicineCathepsin KAnimalsHumansExosomes Multiple MyelomaMultiple myelomaTumor microenvironmentMicroscopy ConfocalBone FormationCell Differentiationmedicine.diseaseMicrovesiclesRAW 264.7 Cellsmedicine.anatomical_structureOncologyTumor microenvironmentCancer researchOsteoclastExosomes Multiple Myeloma; Osteoclasts; Bone FormationResearch PaperSignal Transduction
researchProduct

MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases

2011

INTRODUCTION: The increased bone degradation in osteolytic metastases depends on stimulation of mature osteoclasts and on continuous differentiation of new pre-osteoclasts. Metalloproteinases (MMP)-13 is expressed in a broad range of primary malignant tumours and it is emerging as a novel biomarker. Recent data suggest a direct role of MMP-13 in dissolving bone matrix complementing the activity of MMP-9 and other enzymes. Tumour-microenvironment interactions alter gene expression in malignant breast tumour cells promoting osteolytic bone metastasis. Gene expression profiles revealed that MMP-13 was among the up-regulated genes in tumour-bone interface and its abrogation reduced bone erosion…

Pathologymedicine.medical_specialtyCellular differentiationGalectin 3Mice NudeOsteoclastsBone NeoplasmsBreast NeoplasmsMatrix metalloproteinaseAdenocarcinomaExtracellular matrixMiceOsteoclastCell Line TumorMatrix Metalloproteinase 13medicineAnimalsHumansProtein PrecursorsOSTEOCLASTMedicine(all)MMP13 ; OSTEOCLAST; BREAST TUMORChemistryMMP13Bone metastasisCell Differentiationmedicine.diseaseXenograft Model Antitumor AssaysResorptionExtracellular Matrixmedicine.anatomical_structureCellular MicroenvironmentMatrix Metalloproteinase 9Galectin-3Cancer researchCytokinesFemaleBone marrowBREAST TUMORResearch ArticleBreast Cancer Research : BCR
researchProduct

An in vitro study showing the three-dimensional microenvironment influence over the behavior of head and neck squamous cell carcinoma

2011

Objectives: The Head and Neck Squamous Cell Carcinoma (HNSCC) ranks sixth worldwide. The mechanisms of growth, invasion and metastasis of this pathology are extensively studied and generally related to specific variations in signaling pathways like the PI3K-Akt; however most of these competent studies have been performed bidimensionally, which may hide important questions. This study sought to analyze the influence of the microenvironment upon the behavior of HNSCC. Study Design: The status of pAkt, NF-κB and Cyclin D1 proteins was accessed through immunofluorescence and western blot methods in HNSCC cell lines originating from tongue, pharynx and metastatic lymph node when submitted to a t…

Pathologymedicine.medical_specialtyImmunofluorescenceMetastasisCyclin D1Western blotTumor Cells CulturedTumor MicroenvironmentmedicineHumansCyclin D1Epidermal growth factor receptorGeneral DentistryOral Medicine and Pathologymedicine.diagnostic_testbiologySquamous Cell Carcinoma of Head and NeckNF-kappa B:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseHead and neck squamous-cell carcinomaOtorhinolaryngologyHead and Neck NeoplasmsCell cultureUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellCancer researchbiology.proteinResearch-ArticleSurgerySignal transductionProto-Oncogene Proteins c-aktMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Pathobiology of Hodgkin Lymphoma

2010

Despite its well-known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognizes a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (cHL), reflecting the differences in clinical presentation and behavior, morphology, phenotype, and molec…

Pathologymedicine.medical_specialtybusiness.industryMixed cellularityLymphocyteHematologyReview ArticleHistogenesismedicine.diseasePhenotypeVirusLymphomaPathobiologymedicine.anatomical_structurehemic and lymphatic diseasesmedicineHodgkin lymphomaDiseases of the blood and blood-forming organsRC633-647.5businessWho classificationHodgkin lymphoma; microenvironment.Hodgkin lymphomamicroenvironment.Advances in Hematology
researchProduct

Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Ca…

2018

Here and for the first time, we show that the organometallic compound [Ru(&eta

Pharmaceutical Sciencecisplatin01 natural sciencesAnalytical ChemistrydendrimersCoordination ComplexesDrug DiscoveryMoietyplatinummetallitta116Molecular StructureChemistrymolekyylitnanomedicineNanomedicineChemistry (miscellaneous)MCF-7 CellsMolecular MedicineplatinaDendrimersEpithelial-Mesenchymal TransitionCell SurvivalAntineoplastic Agents.myrkyllisyys010402 general chemistryArticlecancer treatmentlcsh:QD241-441Faculdade de Ciências Exatas e da Engenharialcsh:Organic chemistryDendrimerCell Line TumorOrganometallic CompoundsHumansPhysical and Theoretical ChemistryrutheniumPlatinumCell ProliferationTumor microenvironmentCancer och onkologiToxicitynanocarrierssyöpähoidot010405 organic chemistryOrganic ChemistryMesenchymal stem celltoxicityMesenchymal Stem CellsCombinatorial chemistrykantasolutnanolääketiede0104 chemical scienceslääkkeetTumor progressionCell cultureDrug Resistance NeoplasmmetallodrugsCancer and OncologyCancer cellNanocarriersCaco-2 CellsDrug Screening Assays Antitumor<i>cisplatin</i>hMSCs
researchProduct

CIMT 2014: Next waves in cancer immunotherapy - Report on the 12th annual meeting of the Association for Cancer Immunotherapy

2014

More than 900 scientists around the world visited the 12th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in Mainz, Germany from 6–8 May, 2014. Recent advancements in various spe...

PharmacologyOncologyCell therapymedicine.medical_specialtyTumor microenvironmentCancer immunotherapybusiness.industryInternal medicinemedicine.medical_treatmentImmunologymedicineImmunology and AllergybusinessHuman Vaccines &amp; Immunotherapeutics
researchProduct